Loading news...
Hussman Stratgic Advisors sold 126,000 shares of TG Therapeutics. The fund no longer holds any shares.
Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f
Shares of TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to
TG Therapeutics (TGTX) is upgraded from Hold to Strong Buy as BRIUMVI demonstrates accelerating revenue growth and market share gains in the MS market. TGTX guides for 2026 BRIUMVI U.S. net revenue of $825–$850 million, implying ~40% YoY growth and continued base expansion beyond Q4 2025 run rate. Strategic low pricing, administrative simplification, and subcutaneous formulation development underpin TGTX's competitive positioning and future margin expansion.
Major stock indexes ended lower Wednesday as investors digested the latest batch of bank earnings reports and economic data, while safe-haven gold and silver surged to fresh record highs.
TG Therapeutics (TGTX) surged today following its revenue guidance for FY25 and FY26. The company anticipates FY25 revenue to reach approximately $616 million,
TGTX jumps after preliminary 2025 sales beat guidance. Its bullish 2026 revenue target and multiple Briumvi pipeline milestones also draw attention.
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TG Therapeutics, Inc. (NASDAQ: TGTX) shares climbed in Tuesday's extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here's a look at the details.
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 44th Annual J.P.
TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and Kesimpta. Thanks to the increased demand for Briumvi, TG Therapeutics' EBIT margin increased by 3% year-on-year to 18.2%.
Investors need to pay close attention to TGTX stock based on the movements in the options market lately.
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025.
Advantage Alpha Capital Partners LP lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 30.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,314 shares of the biopharmaceutical company's stock after selling 6,274 shares during the
Creative Planning lessened its stake in TG Therapeutics, Inc. (NASDAQ: TGTX) by 8.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 80,753 shares of the biopharmaceutical company's stock after selling 7,534 shares during the quarter. Creative Planning owned approximately 0.05% of TG Therapeutics worth
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations, slowing growth of Briumvi and concerns about increased competition in the multiple sclerosis market have weighted on its share price. Novartis is testing a less frequently administered version of Kesimpta and Roche's fenebrutinib has generated positive phase 3 results in relapsing multiple sclerosis.
TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneous formulation of Briumvi to become available, with a readout from clinical work possible in late 2026 or early 2027. Kyverna Therapeutics's KYV-101 is emerging as a potential competitor to TGTX's Azer-cel in Multiple Sclerosis, although initial KYV-101 data is from a handful of patients.
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.